IBSA Pharma is part of the IBSA Group, headquartered in Lugano, Switzerland, a world leader in the topical treatment of acute pain and the treatment of hypothyroidism. IBSA markets Licart™ (diclofenac epolamine) topical system 1.3%, a unique patent patch technology for the relief of acute pain associated with minor strains, sprains, and contusions. Licart is the first and only once-a-day topical nonsteroidal anti-inflammatory drug (NSAID) therapy approved by the FDA. It provides targeted pain relief that starts within 1-3 hours of application. IBSA also markets Flector, the original DHEP pain patch.